Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
 
Feedback
Home
c19early.org COVID-19 treatment researchSelect treatment..Select..
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

ZINC085432544 for COVID-19

ZINC085432544 has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Aqeel, I., To Explore the Potential Inhibitors against Multitarget Proteins of COVID 19 using In Silico Study, arXiv, doi:10.48550/arXiv.2409.16486
The global pandemic due to emergence of COVID 19 has created the unrivaled public health crisis. It has huge morbidity rate never comprehended in the recent decades. Researchers have made many efforts to find the optimal solution of this pandemic. Progressively, drug repurposing is an emergent and powerful strategy with saving cost, time, and labor. Lacking of identified repurposed drug candidates against COVID 19 demands more efforts to explore the potential inhibitors for effective cure. In this study, we used the combination of molecular docking and machine learning regression approaches to explore the potential inhibitors for the treatment of COVID 19. We calculated the binding affinities of these drugs to multitarget proteins using molecular docking process. We perform the QSAR modeling by employing various machine learning regression approaches to identify the potential inhibitors against COVID 19. Our findings with best scores of R2 and RMSE demonstrated that our proposed Decision Tree Regression (DTR) model is the most appropriate model to explore the potential inhibitors. We proposed five novel promising inhibitors with their respective Zinc IDs ZINC (3873365, 85432544, 8214470, 85536956, and 261494640) within the range of -19.7 kcal/mol to -12.6 kcal/mol. We further analyzed the physiochemical and pharmacokinetic properties of these most potent inhibitors to examine their behavior. The analysis of these properties is the key factor to promote an effective cure for public health. Our work constructs an efficient structure with which to probe the potential inhibitors against COVID-19, creating the combination of molecular docking with machine learning regression approaches.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit